

### Amendments to the Claims

#### **1-11. (Cancelled)**

**12. (Currently amended)** ~~A partial~~ An isolated peptide having affinity to gp120 represented by formula (1):

H-Asp-Val-Lys-Ala-Gly-R (SEQ ID No. 1)

wherein, in the formula,

H is hydrogen; and

R is OH derived from a carboxyl group or NH<sub>2</sub> derived from an acid amide group.

**13. (Currently amended)** ~~A partial~~ An isolated peptide having affinity to gp120 represented by formula (2):

Al'-Val-Lys-Ala-Gly-R (SEQ ID No. 2)

wherein, in the formula,

Al' is aspartic acid, lysine, valine, glutamic acid, glycine, asparagine, or a tyrosine residue;

and

R is OH derived from a carboxyl group or NH<sub>2</sub> derived from an acid amide group.

**14. (Currently amended)** ~~A partial~~ An isolated peptide having affinity to gp120 represented by formula (3):

H-Asp-Val-Lys-Ala-A5'-R (SEQ ID No. 3)

wherein, in the formula,

H is hydrogen;

A5' is glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, asparagine, glutamine, histidine, lysine, arginine, phenylalanine, tryptophan, proline, or a tyrosine residue; and

R is OH derived from a carboxyl group or NH<sub>2</sub> derived from an acid amide group.

**15. (Currently amended)** ~~A partial~~ An isolated peptide having affinity to gp120 consisting of up to 10 amino acids and comprising the amino acid sequence of Asp-Val-Lys-Ala-Gly (SEQ ID No. 1).

**16. (Previously presented)** The peptide according to claim 15 having affinity to gp120 represented by formula (4):

H-Gly-Asp-Val-Lys-Ala-Gly-R (SEQ ID No. 4),

wherein in the formula,

H is hydrogen; and

R is OH derived from a carboxyl group or NH<sub>2</sub> derived from an acid amide group.

**17. (Previously presented)** The peptide according to claim 15 having affinity to gp120 represented by formula (5):

H-Gly-Gly-Asp-Val-Lys-Ala-Gly-R (SEQ ID No. 5),

wherein in the formula,

H is hydrogen; and

R is OH derived from a carboxyl group or NH<sub>2</sub> derived from an acid amide group.

**18. (Previously presented)** A compound, comprising the peptide as claimed in any one of claims 12 to 17, bound to a macromolecule compound or a medicinal compound.

**19. (Previously presented)** The compound as claimed in claim 18, wherein said macromolecule compound comprises a synthetic polymer or a biopolymer.

**20. (Previously presented)** The compound as claimed in claim 18, wherein the medicinal compound is AZT.

**21. (Previously presented)** A compound, comprising the peptide as claimed in any one of claims 12 to 17, or a pharmaceutically acceptable salt thereof.

**22. (Previously presented)** The compound as claimed in claim 21, wherein the peptide is bound to a carrier.

**23. (Previously presented)** A viral agglutination test compound, comprising the peptide as claimed in any one of claims 12 to 17.

**24. (Previously presented)** A viral test kit, comprising the viral agglutination test compound of claim 23.

**25. (Currently amended)** A method of removing HIV viruses comprising the steps of: contacting the compound as claimed in claim 22, with a liquid sample solution containing the HIV viruses; and absorbing and removing the HIV viruses which have affinity for the compound.